GEN Exclusives

More »

GEN News Highlights

More »
Sep 10, 2007

Innovive Gains European Rights to TMRC’s Oncology Candidate

  • Innovive Pharmaceuticals acquired exclusive rights from TMRC to develop and commercialize Tamibarotene in Europe. In December 2006, the company gained the North American rights to the drug.

    Tamibarotene, a synthetic retinoid drug candidate, will be evaluated in a Phase II pivotal trial in patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans retinoic acid and arsenic trioxide, Innovive reports.

    The terms of the agreement between Innovive and TMRC includes an option to license the use of Tamibarotene in other oncology disease areas including multiple myeloma, myelodysplastic syndromes, and solid tumors, except hepatocellular carcinoma.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »